ModifiedPremera BluecrossPolicy N/A

Prostate Cancer Targeted Therapies

Clinical coverage criteria and benefit management for selected oral and intravenous targeted therapies used to treat various stages of prostate cancer, intended for providers and payers managing pharmacy and medical benefits.

Policy Summary

PayerPremera Bluecross

PolicyProstate Cancer Targeted Therapies

Policy CodePolicy N/A

Change TypeMaterial coverage additions and duration clarifications

Effective DateMay 1, 2026

Next Review Date

Key ActionObtain documentation of HRR/BRCA mutation status and evidence of concurrent androgen deprivation therapy when requesting authorization.

SourceLink

POLICY UPDATE CHANGES

Added coverage indication for Akeega (niraparib and abiraterone acetate) for deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC) when used with prednisone.

Added coverage to Xtandi (enzalutamide) criteria for HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC) when used in combination with Talzenna (talazoparib).

Clarified that medications in this policy are subject to the product's FDA dosage and administration prescribing information and that non-formulary exception authorizations may be approved up to 12 months.

Initial authorization period for oral drugs other than specified agents updated from 3 months to 6 months.

BRCA2-specific indicationAkeega new 2026 indication

≥12 moTypical non-formulary approval duration

6 mo

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial oral drug authorization

423MAGNITUDE cohort size

~53%BRCA proportion (MAGNITUDE)

Coverage Criteria for Targeted Prostate Cancer Therapies

inv-01: Oral agents - agent-specific covered indications and ADT requirement

Covered when the agent-specific indication and companion ADT requirements are met as specified below.

Abirtega (abiraterone): Covered for metastatic castration-resistant prostate cancer (CRPC) OR deleterious or suspected deleterious BRCA-mutated (BRCAm) mCRPC when used in combination with olaparib (Lynparza) OR metastatic high‑risk castration‑sensitive prostate cancer (CSPC). Abirtega (abiraterone) or generic abiraterone must be used in combination with androgen deprivation therapy (ADT) documented by concurrent receipt of a GnRH analog or prior bilateral orchiectomy.

Akeega (niraparib + abiraterone acetate): Covered for deleterious or suspected deleterious BRCA‑mutated (BRCAm) metastatic castration‑resistant prostate cancer (mCRPC) OR deleterious or suspected deleterious BRCA2‑mutated (BRCA2m) metastatic castration‑sensitive prostate cancer (mCSPC). Akeega must be used in combination with ADT (concurrent GnRH analog or prior bilateral orchiectomy) and with prednisone as per trial/FDA labeling.

Erleada (apalutamide): May be considered medically necessary for approved prostate cancer indications; treatment must be used with ADT documented by concurrent GnRH analog or prior bilateral orchiectomy.

Nubeqa (darolutamide): Covered for non‑metastatic castration‑resistant prostate cancer (nmCRPC) OR metastatic castration‑sensitive prostate cancer (mCSPC) OR mCSPC in combination with docetaxel. Nubeqa must be used with ADT documented by concurrent GnRH analog or prior bilateral orchiectomy.

Xtandi (enzalutamide): Covered for castration‑resistant prostate cancer (CRPC) OR metastatic castration‑sensitive prostate cancer (mCSPC) OR non‑metastatic castration‑sensitive prostate cancer with high‑risk biochemical recurrence, and for HRR gene‑mutated mCRPC when used in combination with talazoparib per trial labeling. Xtandi must be used with ADT documented by concurrent GnRH analog or prior bilateral orchiectomy.

Yonsa (abiraterone): Covered for metastatic castration‑resistant prostate cancer (CRPC) when used with ADT (concurrent GnRH analog or prior bilateral orchiectomy) and with methylprednisolone or another corticosteroid, AND only after inadequate response or intolerance to Abirtega (abiraterone) or generic abiraterone.

Zytiga (abiraterone): Covered for metastatic castration‑resistant prostate cancer (CRPC), including use in combination with olaparib for deleterious or suspected deleterious BRCA‑mutated mCRPC; Zytiga must be used with ADT (concurrent GnRH analog or prior bilateral orchiectomy) and with prednisone.

Jevtana (cabazitaxel) IV: Covered for metastatic castration‑resistant prostate cancer when ALL of the following are met: will be used in combination with prednisone AND the individual has been previously treated with a docetaxel‑containing regimen.

inv-02: Not covered / Investigational — 1 top-level node

Other uses: All other uses of the medications listed in this policy are considered investigational.

inv-03: Covered targeted therapy indications — Covered when ALL of the following are met for the specified drug/regimen

Covered when ALL of the following are met for the specified drug/regimen:

Xtandi + Talzenna (enzalutamide + talazoparib) for HRR‑mutated mCRPC: Patient has metastatic castration‑resistant prostate cancer with an HRR gene mutation as determined by circulating tumor DNA or tumor tissue testing; patient will receive enzalutamide 160 mg daily in combination with talazoparib per trial dosing; all patients are receiving ADT (GnRH analog or prior bilateral orchiectomy). Trial evidence (TALAPRO‑2) demonstrated improved radiographic progression‑free survival (rPFS) with rPFS events 33% vs 52%, p<0.0001.HRR gene mutation positive

Akeega (niraparib + abiraterone) for BRCA‑mutated mCRPC: Patient has HRR gene‑mutated mCRPC with deleterious or suspected deleterious BRCA mutation; regimen will be given concurrently with ADT and prednisone as in trials. Magnitude trial showed benefit primarily in the BRCAm subgroup (treatment rPFS events 40% vs placebo 57% in BRCAm subgroup).deleterious or suspected deleterious BRCA mutation

Akeega for BRCA2‑mutated mCSPC:

inv-04: Molecularly defined indications — Covered when specific molecular and indication-based requirements are met

Covered when specific molecular and indication-based requirements are met

Akeega (niraparib + abiraterone acetate): Akeega is indicated and covered for deleterious or suspected deleterious BRCA2‑mutated metastatic castration‑sensitive prostate cancer (mCSPC) when used in combination with prednisone per the updated FDA indication (2026 Update).BRCA2 mutation positive or suspected

Talzenna (talazoparib) HRR‑mutated mCRPC selection: Select individuals for treatment of HRR gene‑mutated mCRPC with Talzenna based on presence of one or more of the following HRR gene mutations: ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C. Note: an FDA‑approved companion test for Talzenna is not currently available.presence of listed HRR gene mutation(s)

All uses of medications not explicitly listed as medically necessary in this policy are considered investigational. Requests for such investigational uses may be denied and will be reviewed according to standard prior authorization and non‑formulary exception processes.

Clinical trial evidence for Akeega (niraparib + abiraterone acetate) shows the observed improvement in radiographic progression‑free survival (rPFS) was driven primarily by patients with BRCA mutations. In the BRCAm subgroup of the trial, 40% of Akeega patients experienced progression or death versus 57% on placebo, whereas in non‑BRCAm patients the rPFS hazard ratio was ~0.99, indicating little or no benefit in that subgroup.

Selection of patients for Talzenna (talazoparib) in HRR‑mutated mCRPC is based on the presence of specific HRR gene mutations (for example, ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C). Note that the document states the FDA‑approved test to detect HRR gene mutation for use with Talzenna is not currently available, which may affect companion test selection and documentation.

Akeega did not demonstrate meaningful rPFS or overall survival benefit in non‑BRCA (non‑BRCAm) HRR‑mutated populations in the trials cited. The policy therefore considers use of Akeega in non‑BRCAm HRR‑mutated patients not medically necessary absent additional supporting evidence, given subgroup hazard ratios (e.g., rPFS HR ~0.99, OS HR ~1.13) that do not indicate benefit.

Coverage is limited to the documented indications, dosing, and duration described in this policy and in the applicable product prescribing information. Requests outside those criteria or outside a member’s benefit limitations are not guaranteed to be covered. Prior authorization and non‑formulary exception reviews follow the policy processes and may be required; failures to meet the policy’s documented criteria or to follow FDA dosing/administration guidance may result in denial.

Provider Actions, Prior Authorization & Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for many oral agents listed in this policy and non-formulary exception reviews may be approved for up to 12 months. Prior authorizations and reviews are subject to the product's FDA dosing and administration prescribing information; failure to follow FDA dosing/administration or to meet policy criteria may result in denial.

Non-formulary exception approvals: up to 12 months for initial and re-authorization reviews when criteria met and clinical response documented.
Prior authorization requirement applies to all oral drugs managed through the pharmacy benefit (see Pharmacy Benefit).
Authorizations and continuations must follow the FDA prescribing information for dosing and administration.

Documentation Required

ADT Documentation Required

Documentation that androgen deprivation therapy (ADT) is being used concurrently is required for many oral agents in this policy. Missing ADT documentation (concurrent GnRH analog therapy or history of bilateral orchiectomy) may trigger denial of coverage.

Coding and Billing Information

HCPCSHCPCSCovered

J9043

Injection, cabazitaxel (Jevtana), 1 mg

Policy history and prior added HCPCS/Codesmixed

No codes listed

HRR mutation prevalence

HRR mutation prevalence23% of metastatic castration-resistant prostate cancer (mCRPC) cases

Most frequent HRR genesBRCA2, ATM, CHEK2, BRCA1 (most commonly observed)

Use in selectionHRR mutation status used to select patients for targeted PARP combinations (e.g., talazoparib + enzalutamide)

Definitions and Terms

Castration-resistant prostate cancer (CRPC)

DefinitionProstate cancer that has progressed despite local therapy and first-line hormonal therapy achieving castrate levels of testosterone

Clinical contextRepresents disease that no longer responds to initial androgen-deprivation approaches; often seen in metastatic settings

DocumentationPolicy requires documentation of ADT (concurrent GnRH analog or bilateral orchiectomy) for agents indicated in CRPC

Androgen deprivation therapy (ADT)

DefinitionTherapy documented by concurrent receipt of a gonadotropin-releasing hormone (GnRH) analog or prior bilateral orchiectomy

Requirement for agentsMany oral agents in this policy (e.g., abiraterone products, Akeega) must be used with ADT as documented

Background

Prostate cancer is an androgen‑driven neoplasm that commonly responds initially to androgen deprivation. When disease progresses despite castrate levels of testosterone, it is termed castration‑resistant prostate cancer (CRPC), a stage associated with substantially worse outcomes and that is the context for many of the targeted systemic therapies addressed in this policy.

Policy Summary

PayerPremera Bluecross

PolicyProstate Cancer Targeted Therapies

Policy CodePolicy N/A

Change TypeMaterial coverage additions and duration clarifications

Effective DateMay 1, 2026

Next Review Date

Key ActionObtain documentation of HRR/BRCA mutation status and evidence of concurrent androgen deprivation therapy when requesting authorization.

SourceLink

On This Page

Patient has deleterious or suspected deleterious BRCA2‑mutated metastatic castration‑sensitive prostate cancer (mCSPC) and is to receive niraparib 200 mg plus abiraterone 1,000 mg with prednisone as per AMPLITUDE/2026 indication; ADT must be in place as per trials.

BRCA2 mutation positive

2026 Update added this mCSPC indication

ADT documentation: office notes, medication list showing GnRH analog, or surgical history documenting bilateral orchiectomy.
Agents requiring ADT documentation include generic abiraterone, Zytiga, Yonsa, Akeega, Erleada, Nubeqa, and Xtandi per policy criteria.

Documentation Required

Documentation Required for Medical Necessity

Medical record documentation must support medical necessity. Include office visit notes with diagnosis, relevant history, physical exam, medication history, and any required clinical/genetic information. Requests for investigational uses or that lack required documentation may be denied.

Required elements: office visit notes (diagnosis, history, physical exam), medication history, documentation of ADT when applicable, and genetic mutation status when indicated (e.g., BRCA/HRR testing).
Follow the product's FDA prescribing information and include documentation that supports the requested indication and dosing.
Investigational uses (not listed as medically necessary) or incomplete documentation are denial triggers.

Step Therapy

Step Therapy / Prior Trial Requirements

Step therapy/history requirements and product-specific trial requirements are enforced per policy history and recent updates. For example, Yonsa requires a prior trial and inadequate response or intolerance to Abirtega or generic abiraterone before coverage is considered.

Yonsa (abiraterone): trial and failure/intolerance to Abirtega or generic abiraterone is required prior to coverage.
Policy updates have historically added and modified step requirements for agents such as Zytiga and generic abiraterone; verify current criteria at time of request.

Billing Rule

Benefit Routing

Follow benefit routing: oral oncology agents listed are managed through the pharmacy benefit; certain agents administered intravenously (e.g., Jevtana) are managed through the medical benefit. Ensure claims are submitted to the correct benefit to avoid processing delays.

Pharmacy benefit: Abirtega, Akeega, Erleada, Nubeqa, Xtandi, Yonsa, Zytiga.
Medical benefit: Jevtana (cabazitaxel).

FormsMedical ADT (GnRH analog) or surgical castration (bilateral orchiectomy)

HRRm

ShorthandHRR gene-mutated abbreviated as HRRm

Context of useUsed throughout policy to denote eligibility for PARP inhibitor–based combinations (e.g., Akeega in HRRm mCRPC/mCSPC cohorts)

TestingMutation status determined by FDA-approved tests or clinical trial assays as referenced in trials

Akeega (combination product)

DefinitionA combination product containing a PARP inhibitor (niraparib) and an androgen biosynthesis inhibitor (abiraterone acetate)

Example regimenNiraparib 200 mg plus abiraterone acetate 1,000 mg with concurrent prednisone as studied in MAGNITUDE and AMPLITUDE

ADT requirementShould be given concurrently with a GnRH analog or following bilateral orchiectomy

HRR gene-mutated mCRPC — included genes

Included HRR genesATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C

Clinical selectionPresence of one or more listed HRR gene mutations may qualify mCRPC patients for targeted PARP combinations

Prevalence noteHRR mutations collectively found in ~23% of mCRPC

BRCA2m mCSPC (Akeega indication)

DefinitionDeleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC) — specifically the 2026 indication for Akeega when used with prednisone

Regimen & dosingNiraparib 200 mg plus abiraterone 1,000 mg with prednisone (per AMPLITUDE/2026 indication); patients required to have ADT

Trial basisEvidence derived from AMPLITUDE cohort where BRCA2m patients were prospectively identified using validated assays